Association between noninvasive clinical indices and fibrosis in adults with MASLD: A cross-sectional study
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD)is a chronic liver condition characterised by hepatic fat accumulation andmetabolic dysfunction. Fibrosis is the key prognostic indicator of adverseoutcomes in MASLD and can be assessed noninvasively using liver stiffnessmeasurement (LSM) by transient elastography (TE). Methods: In this cross-sectional study using NHANES 2017–2020 data, weinvestigated the association between fibrosis stage and several noninvasiveinflammatory and hepatic indices in patients with MASLD. Results: Weighted multivariate analyses showed that higher levels of theinflammatory burden index (IBI) (adjusted OR: 2.13; 95% CI: 1.59–2.87),systemic inflammation response index (SIRI) (1.69; 1.03–2.75), and hepaticsteatosis index (HSI) (2.98; 1.97–4.51) were significantly associated with moreadvanced fibrosis. In contrast, neutrophil-to-lymphocyte ratio (NLR), systemicimmune-inflammation index (SII), and aggregate index of systemic inflammation(AISI) showed no significant associations. These findings were consistent acrossdemographic and behavioural subgroups. Conclusions: Our results suggest that noninvasive indices, particularly IBI,SIRI, and HSI, may help identify MASLD patients at increased risk of advancedfibrosis.
